Integra LifeSciences Expects Q2 Revenue of $411M-$416M Vs $395.8M Est, Adj EPS of $0.60-$0.65 Vs $0.75 Est
Portfolio Pulse from Benzinga Newsdesk
Integra LifeSciences (IART) updates its Q2 revenue forecast to $411M-$416M, surpassing the $395.8M estimate, with adjusted EPS of $0.60-$0.65, below the $0.75 estimate. For 2024, revenue is expected to be $1.672B-$1.687B with adjusted EPS of $3.01-$3.11, reflecting the Acclarent acquisition and organic growth.
May 06, 2024 | 10:03 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Integra LifeSciences raises Q2 revenue expectations to $411M-$416M, above estimates, but lowers adjusted EPS forecast to $0.60-$0.65, below the expected $0.75. 2024 revenue and EPS outlook also updated.
The increase in revenue forecast for Q2 and the full year 2024 indicates strong performance and growth, particularly following the Acclarent acquisition. However, the lower than expected adjusted EPS for Q2 could temper investor enthusiasm, balancing the stock's short-term outlook.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100